A mobile technology to extend the reach of primary care for opioid misuse

项目摘要 阿片类药物使用障碍（OUD）在美国已达到流行病水平，并带来灾难性后果：更多 美国人在2016年和2017年死于阿片类药物过量，而不是整个越南战争。初级保健 提供者（PCP）在抗击这一流行病方面发挥着关键作用，因为他们看到滥用药物的患者 阿片类药物，但尚未依赖除了那些谁已经依赖。然而，有一个严重的 劳动力短缺的供应商培训，以治疗物质使用障碍，而且，此外，病人去星期 或几个月之间的诊所访问时，他们每天都在努力恢复从滥用或依赖。作为 因此，迫切需要为PCP和患者配备工具，以监测和帮助治疗进展。 患者正在努力康复。在这个项目中，我们将开发一个移动的应用程序，其工作名称为 uMAT-R现在，监测病人，提供量身定制的教育材料，指导他们完成 使用循证行为治疗原则的治疗依从性目标，将其与随访联系起来 治疗，包括当地资源的目录，并允许患者向他们的PCP和其他受信任的 成年人，以促进共同决策。对于PCP，我们将建立一个仪表板， 与病人沟通，监测病人对日常生态环境的反应。 评估。这项I期STTR研究有两个特定目的。具体目标1将侧重于患者：在具体 目标1a我们将在患者中测量uMAT-R Now的易用性和参与度;在Specific Aim 1b我们将测量治疗计划依从性的改善程度和阿片类药物滥用行为的改善程度。 在uMAT-R Now参与者与对照组之间停止。具体目标2将侧重于PCP， 测量他们对uMAT-R Now的PCP仪表板和整个工具的满意度。

Project Summary Opioid use disorder (OUD) has reached epidemic levels in the United States, with catastrophic results: more Americans died from opioid overdoses in 2016 and 2017 than in the entirety of the Vietnam War. Primary care providers (PCPs) serve a critical role in combatting this epidemic, because they see patients who misuse opioids but are not yet dependent in addition to those who are already dependent. However, there is a severe workforce shortage of providers trained to treat substance use disorders, and, furthermore, patients go weeks or months between clinic visits when they struggle every day to recover from misuse or dependence. As a result, there is an urgent need to equip both PCPs and patients with tools to monitor and aid the progress of patients working towards recovery. In this project, we will develop a mobile application, with a working title of uMAT-R Now, that monitors patients, provides tailored educational material, guides them through completing treatment adherence goals using evidence-based behavioral therapy principals, links them to follow-up treatment, includes a directory of local resources, and allows patients to message their PCP and other trusted adults to facilitate shared-decision making. For the PCP, we will build a dashboard through which they can communicate with their patients and monitor their patients’ responses to daily ecological momentary assessments. This Phase I STTR study has two Specific Aims. Specific Aim 1 will focus on patients: in Specific Aim 1a we will measure the ease-of-use of and engagement with uMAT-R Now among patients; in Specific Aim 1b we will measure the extent to which treatment plan adherence is improved and opiate misuse behaviors are discontinued among uMAT-R Now participants versus a control group. Specific Aim 2 will focus on PCPs, measuring their satisfaction with uMAT-R Now’s PCP dashboard and the tool as a whole.